A new publication in Cancer Cell shows tumor regression and immune stimulation following oral dosing of a promising new PARP inhibitor to enter clinical development.
Our services – NanoString analysis and CRISPR/Cas9 knock out cell line generation – were used to study the effect of drug inhibition of PARP7 in tumor models.
We are honored to have had the opportunity to collaborate with top immuno-oncology experts leading this project from Ribon Therapeutics, Patricia E. Rao Consulting, and the Department of Systems Biology at Harvard Medical School.
Read on to learn about this cutting-edge research: https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00340-8.